CAI

Caris Life Sciences Inc

31.65

Sep 23 • 3:59 PM ET +0.18 (0.57%)

31.87

Aftermarket • 5:34 PM ET +0.22 (0.68%)

Healthcare Biotechnology USA Mid NASD

Peers: CRL ICLR MEDP QGEN DGX LH IQV A DHR TMO

| Held by: VTI VB VBK IBB SCHA IWP IWR IWF IDNA FTXH

Scroll to Statements

Index	-
Market Cap	8.94B
Enterprise Value	8.60B
Income	105.14M
Sales	989.61M
Book/sh	2.09
Cash/sh	2.81
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1846
IPO	Jun 18, 2025

P/E	85.01
Forward P/E	89.39
PEG	-
P/S	9.04
P/B	15.11
P/C	11.28
P/FCF	76.94
EV/EBITDA	49.44
EV/Sales	8.69
Quick Ratio	4.88
Current Ratio	5.53
Debt/Eq	0.76
LT Debt/Eq	0.75
Option/Short	Yes / Yes

EPS (ttm)	0.37
EPS next Y	0.35
EPS next Q	0.03
EPS this Y	129.72%
EPS next Y	192.53%
EPS next 5Y	-
EPS past 3/5Y	-7.57% -
Sales past 3/5Y	62.87% -
EPS Y/Y TTM	113.10%
Sales Y/Y TTM	85.37%
EPS Q/Q	99.88%
Sales Q/Q	45.38%
Earnings	Aug 05 AMC
EPS/Sales Surpr.	-100.00% 10.75%

Insider Own	55.30%
Insider Trans	-0.58%
Inst Own	49.26%
Inst Trans	-1.28%
ROA	9.62%
ROE	20.13%
ROIC	10.13%
Gross Margin	69.66%
Oper. Margin	15.49%
Profit Margin	10.62%
SMA20	17.45%
SMA50	41.23%
SMA200	50.02%
Trades

Shs Outstand	282.58M
Shs Float	126.33M
Short Float	10.83%
Short Ratio	2.84
Short Interest	13.68M
52W High	33.65 -5.96%
52W Low	14.19 123.04%
Volatility	4.85% 5.48%
ATR (14)	1.49
RSI (14)	74.43
Beta	1.01
Rel Volume	0.90
Avg Volume	4.82M
Volume	4,359,721

Perf Week	12.19%
Perf Month	21.13%
Perf Quarter	74.38%
Perf Half Y	64.50%
Perf YTD	17.31%
Perf Year	-1.40%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.64
Target Price	28.00
Prev Close	31.47
Price	31.65
Change %	0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-26	Initiated	UBS	Neutral	$28
Jun-02-26	Resumed	Wolfe Research	Peer Perform
Apr-13-26	Initiated	Jefferies	Buy	$28
Apr-10-26	Initiated	Piper Sandler	Neutral	$21
Apr-01-26	Initiated	Goldman	Buy	$27
Feb-17-26	Initiated	Robert W. Baird	Outperform	$26
Dec-02-25	Initiated	Canaccord Genuity	Hold	$28
Jul-14-25	Initiated	Wolfe Research	Outperform	$32
Jul-14-25	Initiated	TD Cowen	Buy	$32
Jul-14-25	Initiated	JP Morgan	Overweight	$31
Jul-14-25	Initiated	Guggenheim	Buy	$32
Jul-14-25	Initiated	Evercore ISI	Outperform	$33
Jul-14-25	Initiated	Citigroup	Buy	$34
Jul-14-25	Initiated	BTIG Research	Buy	$38
Jul-14-25	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

Today 08:39AM	FDA advisers are reviewing a multicancer-detection test. Medicare coverage could follow. (MarketWatch)
Sep-22-26 02:02PM	Caris Life Sciences Coasts Past A Buy Point; Why This Texas Biotech Researcher Deserves A Look (Investor's Business Daily)
Sep-18-26 04:26AM	Caris Life Sciences Stock Jumped 10% Yesterday. Heres Where Shares Could Go Further in 2026. (TIKR)
Sep-08-26 06:30AM	Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect (PR Newswire)
Sep-02-26 08:30AM	Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer (PR Newswire)
08:30AM	Loading…
Aug-27-26 08:30AM	Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer (PR Newswire)
Aug-06-26 08:30AM	Caris Life Sciences, Inc. Q2 2026 Earnings Call Summary (Moby) +21.58%
01:05AM	Caris Life Sciences Inc (CAI) (Q2 2026) Earnings Call Highlights: Record Revenue and Volume ... (GuruFocus.com)
Aug-05-26 04:05PM	Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance (PR Newswire)
Jul-16-26 08:30AM	Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026 (PR Newswire) -5.61%
Jul-14-26 08:30AM	Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing (PR Newswire)
Jul-01-26 08:30AM	Caris Life Sciences Launches Caris Detect, the World's Most Sensitive and Comprehensive Multi-Cancer Early Detection Blood Test (PR Newswire) +5.22%
Jun-16-26 11:26AM	Caris Life Sciences Announces That Its Dual Listing on NYSE Texas (NYSE)
08:30AM	Caris Life Sciences Announces Dual Listing on NYSE Texas (PR Newswire)
Jun-08-26 08:30AM	Caris Life Sciences Announces Share Repurchase Program (PR Newswire)
08:30AM	Loading…
May-26-26 08:30AM	Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing (PR Newswire)
May-15-26 08:30AM	Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek (PR Newswire)
May-11-26 12:15PM	Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels (PR Newswire)
May-08-26 04:05PM	Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood-Based Testing Authorization (PR Newswire) -18.60%
May-07-26 04:05PM	Caris Life Sciences Reports First Quarter 2026 Financial Results (PR Newswire)
May-05-26 08:30AM	Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis (PR Newswire)
May-04-26 08:30AM	Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies (PR Newswire)
Apr-29-26 08:30AM	Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients (PR Newswire)
Apr-24-26 08:30AM	Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference (PR Newswire)
Apr-20-26 08:30AM	Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026 (PR Newswire)
Apr-17-26 08:30AM	Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center (PR Newswire)
Apr-15-26 08:30AM	Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients (PR Newswire)
Apr-08-26 08:30AM	Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients (PR Newswire)
Apr-02-26 08:30AM	Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies (PR Newswire)
Mar-31-26 06:00PM	Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect (PR Newswire) +6.11% +6.99%
08:30AM	Loading…
Mar-26-26 08:30AM	Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer (PR Newswire)
Mar-25-26 08:30AM	Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026 (PR Newswire)
Mar-24-26 08:30AM	Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month (PR Newswire)
Mar-20-26 08:30AM	Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients (PR Newswire)
Mar-16-26 08:30AM	Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer (PR Newswire)
Mar-11-26 08:30AM	Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting (PR Newswire)
Mar-09-26 08:30AM	Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer (PR Newswire)
Mar-03-26 11:40AM	BTSG vs. CAI: Which Stock Is the Better Value Option? (Zacks) -6.20%
Feb-28-26 08:00PM	Caris Life Sciences Inc (CAI) Q4 2025 Earnings Call Highlights: Record Revenue Surge and ... (GuruFocus.com)
Feb-27-26 04:40PM	Stocks Settle Lower as Bank Shares Tumble and Tech Stocks Fall (Barchart)
11:14AM	Stocks Retreat on AI Disruption Concerns and Geopolitical Risks (Barchart)
10:07AM	Stocks Fall on AI Fears and Stronger-Than-Expected Producer Prices (Barchart)
07:00AM	Cancer Test Maker Caris Life Sciences Unveils Breakthrough In Early Cancer Detection, Profit Surprise (Benzinga)
03:41AM	Caris Life Sciences (CAI) Adds New AI-powered Breast Cancer Signature to its Report (Insider Monkey)
Feb-26-26 10:07PM	Caris Life Sciences Q4 Earnings Call Highlights (MarketBeat) +5.08%
06:00PM	Caris Life Sciences Completes Interim Readout of Achieve 1 Study (PR Newswire)
04:05PM	Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook (PR Newswire)
Feb-25-26 01:58AM	Baird Initiates Coverage of Caris Life Sciences, Inc. (CAI) with an Outperform Rating (Insider Monkey)
Feb-24-26 08:30AM	Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug (PR Newswire)
Feb-23-26 08:30AM	Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference (PR Newswire) -9.68%
Feb-20-26 01:21PM	Russell 2000 Drop, EM Stocks Hit Records After Court's Tariff Ruling: What's Moving Markets Friday? (Benzinga) -6.33%
Feb-09-26 08:30AM	Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26 (PR Newswire)
Jan-28-26 08:30AM	Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan (PR Newswire)
Jan-12-26 12:43PM	Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? (Benzinga) -10.21%
08:30AM	Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results (PR Newswire)
08:00AM	Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect (PR Newswire)
Jan-05-26 08:30AM	Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-25 08:30AM	The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute (PR Newswire)
Dec-16-25 08:30AM	Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need (PR Newswire)
Dec-08-25 09:55AM	Can Caris Life Sciences,?Inc. (CAI) Climb 32.81% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-04-25 08:30AM	Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium (PR Newswire)
Dec-02-25 01:53PM	IP Oh No? Recent Stock Market Debuts Have Fizzled. (Barrons.com)
08:30AM	The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute (PR Newswire)
Nov-21-25 08:30AM	Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class (PR Newswire)
Nov-17-25 08:30AM	Caris Life Sciences to Attend Q4 2025 Investor Conferences (PR Newswire)
Nov-05-25 04:05PM	Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance (PR Newswire) -6.32% -15.75%
Nov-04-25 07:27AM	What To Expect From Caris Life Sciences Inc (CAI) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 08:41AM	Caris Life Sciences announces collaborative new research on TET2 (TipRanks) +5.91%
Oct-29-25 08:30AM	Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy Response (PR Newswire)
Oct-23-25 08:30AM	Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025 (PR Newswire) +5.39%
Oct-14-25 08:30AM	Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025 (PR Newswire)
Oct-01-25 01:43PM	Caris Life Sciences, Inc. (CAI) Soars 81% YoY with $181M Q2 Revenue (Insider Monkey)
Sep-18-25 08:40AM	Strong Performance Lifted Caris Life Sciences (CAI) in Q2 (Insider Monkey)
Sep-11-25 11:17AM	Caris Life Sciences, Inc. (CAI) Secures FDA Nod for Revolutionary Tumor Profiling Test (Insider Monkey)
08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks)
Aug-15-25 08:30AM	Caris Life Sciences Demonstrates Scientific Rigor with Clinical Validation of FDA-Approved MI Cancer Seek (PR Newswire)
Aug-13-25 08:30AM	New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups (PR Newswire) +5.61%
Aug-12-25 04:05PM	Caris Life Sciences Reports Second Quarter 2025 Financial Results (PR Newswire) +7.45%
Aug-06-25 08:30AM	Caris Life Sciences Publishes Study Showing AI Signature-positive Breast Cancer Patients Live Almost Twice as Long as AI-negative Patients When Treated with a Checkpoint Inhibitor (PR Newswire)
Aug-05-25 08:30AM	Caris Life Sciences Publishes Study Showing its Multi-Layer AI-Based Tissue of Origin Predictions are Best-in-Class and Identify when Patients have been Misdiagnosed (PR Newswire)
Jul-23-25 08:30AM	Caris Life Sciences to Report Second Quarter 2025 Financial Results on August 12, 2025 (PR Newswire)
Jul-22-25 08:30AM	Caris Life Sciences Validates and Extends Findings on Tumor-Infiltrating Clonal Hematopoiesis (PR Newswire) +7.07%
Jul-08-25 06:30AM	Caris Life Sciences Announces New Study Demonstrating the Power and Clinical Utility of its Caris Assure Blood-Based Assay for Multi-Cancer Early Detection, Minimal Residual Disease and Therapy Selection (PR Newswire)
Jun-20-25 05:01AM	Caris Life Sciences indicated to open at $30, IPO priced at $21 per share (TipRanks)
Jun-18-25 02:50PM	This 'AI TechBio' company goes public as IPO demand spreads to biotech (MarketWatch)
01:37PM	The IPO Market Extends Its Comeback (Barrons.com)

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX.

ChairmanDr. David Dean Halbert M.D.

Executive Vice Chairman & Executive VPMr. Brian J. Brille J.D.

M.S.Dr. David Spetzler M.B.A.

Senior VPMr. J. Russel Denton

Senior VPMr. Luke Power

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Denton John Russel	See Remarks	Sep 22 '26	Sale	31.82	7,500	238,626	174,855	Sep 23 05:06 PM
JOHN RUSSEL DENTON	Officer	Sep 22 '26	Proposed Sale	31.82	7,500	238,626		Sep 22 04:08 PM
Brille Brian J	See Remarks	Sep 17 '26	Option Exercise	2.44	400,000	976,000	630,303	Sep 17 06:08 PM
Brille Brian J	See Remarks	Sep 17 '26	Sale	30.33	400,000	12,132,080	230,303	Sep 17 06:08 PM
BRIAN J BRILLE	Officer	Sep 17 '26	Proposed Sale	30.33	400,000	12,132,080		Sep 17 04:34 PM
Spetzler David Baxley	President	Sep 03 '26	Option Exercise	2.44	1,000,000	2,440,000	1,530,083	Sep 04 04:59 PM
Spetzler David Baxley	President	Sep 04 '26	Option Exercise	2.44	250,000	610,000	1,302,083	Sep 04 04:59 PM
Spetzler David Baxley	President	Sep 03 '26	Sale	24.86	478,000	11,882,990	1,052,083	Sep 04 04:59 PM
Spetzler David Baxley	President	Sep 04 '26	Sale	24.76	119,212	2,951,117	1,182,871	Sep 04 04:59 PM
DAVID SPETZLER	Officer	Sep 04 '26	Proposed Sale	24.76	119,212	2,951,117		Sep 04 04:43 PM
DAVID SPETZLER	Officer	Sep 03 '26	Proposed Sale	24.86	478,000	11,882,984		Sep 03 04:45 PM
GEORGE H POSTE REVOCABLE TRUST	Former Affiliate	Aug 24 '26	Proposed Sale	26.06	100,000	2,606,320		Aug 24 04:29 PM
GEORGE H POSTE	Director	Aug 07 '26	Proposed Sale	21.42	30,000	642,633		Aug 07 05:12 PM
GEORGE H POSTE	Director	Aug 03 '26	Proposed Sale	16.25	20,000	325,000		Aug 03 04:10 PM
HALBERT JON	Director	May 15 '26	Buy	14.56	68,000	990,080	704,598	Jul 13 07:06 AM
Vacirca Jeff L	Director	May 11 '26	Buy	16.15	31,050	501,426	49,671	May 12 08:22 AM
CASTLEMAN PETER M	Director	Jan 09 '26	Option Exercise	18.60	2,500	46,500	18,629	Jan 13 06:37 PM
Power Luke Thomas	See Remarks	Dec 11 '25	Option Exercise	2.44	62,250	151,890	161,821	Dec 12 07:39 PM
Power Luke Thomas	See Remarks	Dec 11 '25	Sale	26.58	62,250	1,654,461	99,571	Dec 12 07:39 PM
LUKE POWER	Officer	Dec 11 '25	Proposed Sale	27.10	62,250	1,686,975		Dec 11 04:27 PM
Denton John Russel	See Remarks	Nov 07 '25	Buy	24.09	4,184	100,793	9,184	Nov 10 08:12 AM
Spetzler David Baxley	President	Nov 07 '25	Buy	23.85	400	9,540	460,777	Nov 10 08:11 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CAI

Caris Life Sciences Inc

Upgrade your Finviz experience